Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Clinical trial NCT00189345 · COMPLETED

Trial details

NCT number: NCT00189345
Sponsor: AGO Study Group
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Fallopian Tube Neoplasms Peritoneal Neoplasms

Start date: 2004-05-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.